Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1997; 78(01): 489-496DOI: 10.1055/s-0038-1657575 Clinical use of low molecular weight heparins Schattauer GmbH Stuttgart The Treatment of Deep Vein Thrombosis and Pulmonary Embolism Franktien Turkstra Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands , Maira M W Koopman Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands , Harry R Büller Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (1546 kb) References References 1 Huisman MV, Büller HR, ten Cate JW, van Royen EA, Kersten MJ, Baks R. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498-502 2 Dorfman GS, Cronan JJ, Tupper TB, Messersmith RN, Denny DF, Lee CH. Occult pulmonary embolism: a common occurrence in patients with deep venous thrombosis. AJR 1987; 148: 263-266 3 Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-445 4 Hull RD, Hirsh J, Carter CJ, Jay RJ, Dodd PE, Ockelford PA. et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Int Med 1983; 98: 891-899 5 Kruit VMJ, de Boer AC, Sing AK, van Roon F. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med 1991; 230: 333-339 6 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM. et al. The long-term clinical course of acute deep vein thrombosis. Annals 1996; 125: 1-7 7 Byeth RJ. et al. Long term outcomes of patients with deep vein thrombosis. Arch Int Med 1995; 155: 1031-1037 8 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245 9 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643 10 Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d’Azemar P, Coquart JP. Randomised trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85: 1380-1389 11 Kuijer PMM, Gallus AS, Cade JF, Buller HR. A randomised comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism. Thromb Haemost 1995; 73: 974 (abstract) 12 The Columbus. Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Blood 1996; 88: 626 (abstract) 13 Mahomer H, Castleberry JW, Coleman WO. Attempts to restore function in major veins which are the site of massive thrombosis. Annals Surg 1957; 146: 510-522 14 Mavor GE. Deep vein thrombosis. Surgical Management. Br Med J 1969; 4: 680-682 15 Haller JA, Abrams BL. Use of thrombectomy in the treatment of acute iliofemoral venous thrombosis in forty-five patients. Ann Surg 1963; 158: 561-566 16 Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. Ann Surg 1968; 04: 620-626 17 Johanssen E, Nordlander S, Zetterquist S. Venous thrombectomy in the lower extremity-clinical, phlebographic and plethysmo- graphic evaluation of early and late results. Acta Chir Scand 1973; 139: 511-516 18 Young AE, Thomas ML, Browse NL. Comparison between sequelae of surgical and medical treatment of venous thromboembolism. Br Med J 1974; 04: 127-130 19 Prager M, Huk I, Kretschmer G, Polterauer P. Chirurgische Therapie der akuten BeinBecken-Venen thrombose. Acta Med Austriaca 1994; 21: 102-104 20 Mickley V, Friedrich JM, Hutschenreiter S, Sunder-Plassmann L. Langzeitergebnisse nach perkutan-transluminaler Angioplastie und Stentimplantation bei venbsen Stenosen nach transfemoraler Thrombektomie. Vasa 1993; 22: 44-52 21 Kniemeyer HW, Sandmann W, Schwindt C, Grabitz K, Torsello G, Stühmeier K. Thrombectomy with arteriovenous fistula for embolizing deep venous thrombosis: an alternative therapy for prevention of recurrent pulmonary embolism. Clin Invest 1993; 72: 40-45 22 Plate G, Einarsson E, Ohlin P, Jensen R, Qvarfordt P, Eklöf B. Thrombectomy with temporary arteriovenous fistula: The treatment of choice in acute iliofemoral venous thrombosis. J Vase Surg 1984; 1: 867-876 23 Plate G, Akesson H, Einarsson E, Ohlin P, Eklof B. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. Eur J Cardiovasc Surg 1990; 4: 483-489 24 Jakob H, Vahl C, Lange R, Micek M, Tanzeem A, Hagl S. Modified surgical concept for fulminant pulmonary embolism. Eur J Cardio-throac Surg 1995; 9: 557-561 25 Meyer G, Tamisier D, Sors H. et al. Pulmonary embolectomy: a 20-year experience at one centre. Ann Thorac Surg 1991; 51: 232-236 26 Robertson BR, Nilsson IM, Nylander G. Value of streptokinase and heparin in treatment of acute deep venous thrombosis. Acta Chir Scand 1968; 134: 203-208 27 Kakkar VV, Flanc C, Howe CT, O’Shea M, Flute P.T. Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and Alvin. Br Med J 1969; 1: 806-810 28 Robertson BR, Nilsson IM, Nylander G. Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chri Scand 1970; 136: 173-180 29 Tsapogas MJ, Peabody RA, Wu KT, Karmody AM, Devaraj KT, Eckert C. Controlled study of thrombolytic therapy in deep vein thrombosis. Surgery 1973; 74: 973-984 30 Porter JM, Seaman AJ, Common HH, Rosch J, Eidemiller LR, Calhoun AD. Comparison of heparin and streptokinase in the treatment of venous thrombosis. Am Surg 1975; 41: 511-519 31 Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funstone MR, Smith JA. et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838-843 32 Kakkar W, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. Am J Surg 1985; 150: 54-63 33 Schulman S, Granqvist S, Juhlin-Dannfelt A, Lockner D. Longterm sequelae of calf vein thrombosis treated with heparin or low- dose streptokinase. Acta Med Scand 1986; 219: 349-357 34 Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J. et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88: 235-240 35 Turpie AGG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, Gent M. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Chest 1990; 97: 172S-175S 36 Lensing AWA, Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. In: Vascular Diagnosis. Bernstein EF. (eds). Mosby-Year Book; St Louis: 1993. pp. 875-879 37 The Urokinase. Pulmonary Embolism Trial. A national cooperative study. Am Heart J 1973; 47 (Suppl. 02) 1-108 38 Dalia-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator multicenter study 2. J Am Coll Cardiol 1992; 20: 520-526 39 Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-1479 40 Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva A, Come PC, Lee RT, Parker JA, Mogtader A, McDonough J, Braunwald E. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511 41 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574 42 Brandjes DPM, Heijboer H, Büller HR. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-1489 43 Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Int Med 1992; 116: 279-284 44 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. New Engl J Med 1986; 315: 1109-1114 45 Gallus A, Jackaman J, Tillet J. et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 02: 1293-1296 46 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl J Med 1972; 287: 325-327 47 Cruickshank MY, Levine MN, Hirsh J. et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-337 48 Hirsh J, Levine NW. Low molecular weight heparin. Blood 1992; 79: 1-17 49 Lensing AWA, Hirsh J, Buller HR. Diagnosis of venous thrombosis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Coleman RW, Hirsh J, Marder VJ, Salzman EW. (eds). Lippincott, Philadelphia: 1982. pp. 1297-1321 50 Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep vein thrombosis. Ann Intern Med 1981; 94: 439-444 51 Lagerstedt Cl, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 02: 515-58 52 Hull RD, Hirsh J, Carter C. et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: A randomized trial. Ann Intern Med 1985; 102: 21-26 53 Huisman MV, Buller HR, ten CateJW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314: 823-826 54 Heijboer H, Buller HR, Lensing AWA, Turpie AGG, Colly LP, ten Cate JW. A comparison of real-time ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med 1993; 329: 1365-1369 55 Sluzewski M, Koopman MMW, Schuur KH, Vroonhoven ThJMV, van Ruijs JHJ. Influence of negative ultrasound findings on the management of in- and outpatients with suspected deep-vein thrombosis. Eur J Radiol 1991; 13: 174-177 56 Hull RD, Raskob GE, Coates G, Panju AA, Gill GJ. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med 1989; 149: 2549-2555 57 Hull RD, Raskob GE, Ginsberg JS, Panju AA, Brill-Edwards P, Coates G. et al. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Int Med 1994; 154: 289-297 58 Wells P, Ginsberg J, Anderson D, Hirsh J, Turpie A, Bormanis J, Kearon C, Weitz J. The use of a clinical model in a prospective management study of patients with suspected pulmonary embolism. Blood 1996; 88: 625s (abstract) 59 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nad Cancer Inst 1959; 22: 719-748 60 Prandoni P, Lensing AWA, Büller RR. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445 61 Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d’Azemar P, Büller M. on behalf of the TASMAN-study group Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687 62 Lopaciuk S, Meissner AJ, Filipecki S. et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14-18 63 Lindmarker P, Holmström M, Granqvist S. et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-190 64 Fiessinger JN, Fernandez ML, Gatterer E, Ohlsson CG. Fragmin once daily versus continuous infusion of heparin in the treatment of DVT — A European Multicentre Trial. Haemost 1994; 24 (Suppl. 01) 44 65 Luomanmaki K, and the Finnish multicentre group Hallert C, Kim H. LMWH (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemaost 1994; 24 (Suppl. 01) 248 66 Simonneau G, Charbonnier B, Decousus H. et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. Arch Intern Med 1993; 153: 1541-1546 67 Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334: 677-681 68 Hull RD, Raskob GE, Pineo GF. et al. Subcutaneous low- molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-981 69 Duroux P. A collaborative European Multicentre Study: a randomised trial of subcutaneous LMWH (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251-256 70 Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between LMWH (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-817 71 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Loerum F, Scheel B, Sortland O, Vinje B. Subcutaneous treatment of deep venous thrombosis: a comparison of unfractionated and LMWH. Haemost 1986; 16 (Suppl. 01) 30-37 72 Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1990; 64: 506-510 73 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Eng J Med 1995; 332: 1330-1335 74 Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-1828 75 Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B, Sors H. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of non massive pulmonary embolism: an open randomised pilot study. Thromb Haemostas 1995; 74: 1432-1435 76 Simonneau G, Sors H, Charbonnier B, Beau B. for the THESEE group Once daily low molecular weight heparin (LMWH) Tinzaparin versus unfractionated heparin (UFH) in the treatment of pulmonary embolism (PE). Haemostasis 1996; 26 (Suppl. 03) 006 (abstract)
